These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Sheng H; Shao J; O'Mahony CA; Lamps L; Albo D; Isakson PC; Berger DH; DuBois RN; Beauchamp RD Oncogene; 1999 Jan; 18(4):855-67. PubMed ID: 10023661 [TBL] [Abstract][Full Text] [Related]
3. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. Erickson BA; Longo WE; Panesar N; Mazuski JE; Kaminski DL J Surg Res; 1999 Jan; 81(1):101-7. PubMed ID: 9889067 [TBL] [Abstract][Full Text] [Related]
4. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687 [TBL] [Abstract][Full Text] [Related]
6. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta. Du J; Jiang B; Coffey RJ; Barnard J Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 downregulates inducible nitric oxide synthase in rat intestinal epithelial cells. Kobayashi O; Miwa H; Watanabe S; Tsujii M; Dubois RN; Sato N Am J Physiol Gastrointest Liver Physiol; 2001 Sep; 281(3):G688-96. PubMed ID: 11518681 [TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Sheng H; Shao J; Hooton EB; Tsujii M; DuBois RN; Beauchamp RD Cell Growth Differ; 1997 Apr; 8(4):463-70. PubMed ID: 9101092 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Komatsu K; Buchanan FG; Katkuri S; Morrow JD; Inoue H; Otaka M; Watanabe S; DuBois RN Gastroenterology; 2005 Aug; 129(2):577-90. PubMed ID: 16083714 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. Sheng H; Shao J; Kirkland SC; Isakson P; Coffey RJ; Morrow J; Beauchamp RD; DuBois RN J Clin Invest; 1997 May; 99(9):2254-9. PubMed ID: 9151799 [TBL] [Abstract][Full Text] [Related]
11. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells. Kim HS; Kim JW; Gang J; Wen J; Koh SS; Koh JS; Chung HH; Song SY Toxicol Appl Pharmacol; 2006 Sep; 215(3):317-29. PubMed ID: 16712893 [TBL] [Abstract][Full Text] [Related]
12. Induction of cyclooxygenase-2 in Ras-transformed human mammary epithelial cells undergoing apoptosis. Na HK; Surh YJ Ann N Y Acad Sci; 2002 Nov; 973():153-60. PubMed ID: 12485854 [TBL] [Abstract][Full Text] [Related]
13. Transformation by oncogenic Ras expands the early genomic response to transforming growth factor beta in intestinal epithelial cells. Allen CE; Du J; Jiang B; Huang Q; Yakovich AJ; Barnard JA Neoplasia; 2008 Oct; 10(10):1073-82. PubMed ID: 18813357 [TBL] [Abstract][Full Text] [Related]
18. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Zweifel BS; Davis TW; Ornberg RL; Masferrer JL Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270 [TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. Sheng H; Shao J; Dixon DA; Williams CS; Prescott SM; DuBois RN; Beauchamp RD J Biol Chem; 2000 Mar; 275(9):6628-35. PubMed ID: 10692471 [TBL] [Abstract][Full Text] [Related]
20. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]